Samsung Biologics Participates in 2025 BioProcess International

by Jeong Donghoon

Published 18 Sep.2025 08:38(KST)

Highlighting Differentiated CDMO Competitiveness on the Global Stage

Samsung Biologics announced on the 18th that it participated in the 2025 BioProcess International (BPI), a global bio-industry conference.

On the 16th (local time), Taehee Lee, Executive Director of the Antibody Culture PD Team at Samsung Biologics, is presenting at the speaking session. Samsung Biologics

BPI is a world-renowned bio event where the latest technologies across all areas of biopharmaceutical development, production, and analysis are shared, and partnerships are discussed. It is held annually in the United States, Europe, and Asia. This year’s event is taking place in Boston, United States, from September 15 to 18 (local time), with over 250 companies setting up exhibition booths and more than 3,200 global experts expected to attend.

Samsung Biologics, which has participated in BPI for eight consecutive years since 2018, set up its own booth again this year to showcase its comprehensive support capabilities across the entire biopharmaceutical lifecycle, from contract research organization (CRO) to contract manufacturing organization (CMO). The booth actively promoted Samsung Organoids, differentiated contract development organization (CDO) service competitiveness, and an expanded portfolio including antibody-drug conjugates (ADC) and messenger RNA (mRNA) through wall graphics.

On Tuesday the 16th, Samsung Biologics employees highlighted the company's CDO competitiveness during a presentation session. Lee Taehee, Executive Director of the Antibody Culture PD Team, participated as a speaker in the session, presenting strategies to accelerate clients’ new drug development timelines under the theme “Accelerating New Drug Development: From Feasibility Assessment to IND Submission.”

Lee explained that by conducting early-stage feasibility assessments, establishing risk-based chemistry, manufacturing, and control (CMC) plans, and introducing parallel workflows, it is possible to reduce complexity and increase development speed without compromising quality. He emphasized that these approaches can effectively shorten the period from candidate selection to IND (Investigational New Drug) application submission.

Following this, Heo Gyeyeon, Head of the CMC Support Team, presented a poster on “Joint Analytical Method Qualification: Strategies to Enhance Technology Transfer Efficiency and Accelerate Development Timelines for cGMP Production between the CDO and QC Departments.”

“Joint Analytical Method Qualification” refers to a process in which the CDO department, which develops quality analytical methods for clinical materials, and the QC department, which verifies them, jointly assess qualification. By integrating the previously separate processes of method development and evaluation within each department, this approach eliminates the need for a technology transfer stage that was previously essential for moving from development to evaluation. This helps clients accelerate their drug development timelines. Additionally, it reduces the possibility of errors during technology transfer, thereby improving the completeness of analytical methods.

Meanwhile, Samsung Biologics introduced its new CDO slogan last year, “Agile. Flexible. Focused on You.” and has been focusing on promoting its client-tailored CDO competitiveness. The company also plans to continuously strengthen its technological competitiveness to respond to the evolving biopharmaceutical market.